Internal Medicine

ASCO 2023

Questions discussed in this category

What are your top takeaways in Hematologic Malignancies from ASCO 2023?

8 Answers available

Papers discussed in this category

Leukemia, 2014-03

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

Lancet Oncol, 2021 Nov 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

Blood, 2022 Oct 20

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Jun 05

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

Related Topics in Internal Medicine